​

Funding Round

Series B - Icosavax

Series B - Icosavax

Investment Firm

Overview

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Announced Date

Apr 07, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

RA Capital Management

RA Capital Management

RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

9

Investor Name
Participant InvestorRA Capital Management
Participant InvestorSanofi Ventures
Participant Investor+ND Capital
Participant InvestorAdams Street Partners
Participant InvestorOmega Funds

Round Details and Background

Icosavax raised $100000000 on 2021-04-07 in Series B

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Company Funding History

7

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 30, 2020
Grant - Icosavax
1-10.0M
Jan 01, 2017
Pre Seed Round - Icosavax
1-undefined
May 22, 2023
Post-IPO Equity - Icosavax
3-67.8M
Aug 01, 2020
Grant - Icosavax
1-6.5M

Recent Activity

There is no recent news or activity for this profile.